Bernie Berry, III
Bernie Berry is the former President and owner of Carr Metal Products, Inc. (CMP), a world‐wide leader in the design, development, and manufacturing of precision sheet metal and plastic fabrications. Mr. Berry joined CMP, a firm his father co‐founded, in 1975. He was appointed president in 1985 where he would direct the company’s activities and growth strategies. Among his many accomplishments, Mr. Berry developed an environment of innovation and superior product development by embracing new technologies and advanced manufacturing principals. Carr Metal Products was acquired by Precimed Group, a leading technology‐driven supplier to the orthopedic industry in 2006, which resulted in Mr. Berry’s company being renamed Precimed CMP. In 2008, Precimed was purchased by Greatbatch, Inc., a leading designer and manufacturer of high quality, innovative products and systems to customers in the cardiac, neuromodulation, orthopedics and commercial markets. Mr. Berry is a graduate of Purdue University and remains an active consultant and advisor to the medical device industry.
Stephen (Steve) Burns
Steve joins our Board with over 40 years of professional and legal experience in the Indianapolis area. He holds a Bachelor of Arts degree from Denison University and earned his JD from the Indiana University School of Law in 1968. Steve was a practicing attorney for over twenty years, and served as the President and CEO of Wheaton Van Lines from January 1988 to January 2009 and now serves as Chairman of the Board. He has been active in many professional, social and civic organizations throughout his career.
Bryan Hughes is the Director and Group Head – Medical Technology Investment Banking at P & M Corporate Finance, LLC. (PMCF). PMCF is an investment bank providing merger and acquisition services to companies throughout North America and Europe. Mr. Hughes has over 10 years of business and transaction advisory experience, specializing in assisting clients with mergers and acquisitions, leveraged buyouts, private placements, financings, valuation and strategic consulting. His clients have ranged from global life sciences companies to small, privately held businesses. In addition to leading the firm’s Medical Technology team, he has also completed transactions in business services, consumer and industrial sectors. Mr. Hughes earned a B.B.A. with emphases in finance and accounting from the Stephen M. Ross School of Business at the University of Michigan. He is a licensed securities representative, holding Series 7 and 63 registrations. He has written numerous articles and is a frequent speaker on healthcare investment banking and related financial topics.
Marie Infante is a healthcare lawyer with more than twenty-five years of experience advising clients in health policy, reimbursement, regulatory, governance and compliance matters. She has served in leadership and executive positions in for profit, and not for profit healthcare companies. Most recently, as Senior Vice President, Chief Compliance Officer and General Counsel for Healthcare Law for Golden Living, she was responsible for compliance, ethics and regulatory issues for over 60,000 patients and more than 40,000 employees in post-acute and rehabilitation settings. Most importantly, her clinical experience includes fifteen years as a clinical specialist in orthopaedic nursing. Recognized by national and state organizations for her advocacy on behalf of patients and healthcare providers, she remains an active consultant and senior advisor in the healthcare industry. Ms. Infante is a graduate of the University of Maryland where she received her BSN and MS. She also has an MBA from Loyola University and earned her JD at the Catholic University of America in Washington DC.
Chief Financial Officer & Chief Operating Officer
Fred Hite is currently OrthoPediatrics’ Chief Financial Officer & Chief Operating Officer, joining the Company in February, 2015. Prior to joining OrthoPediatrics, Mr. Hite spent over ten years as the CFO and Investor Relations Officer of Symmetry Medical, a NYSE listed publicly traded company. During his time at Symmetry Medical, the company completed an Initial Public Offering (IPO), a secondary offering and nine acquisitions. Prior to Symmetry Medical, Mr. Hite spent thirteen years with General Electric in a variety of financial positions and areas including commercial, manufacturing, sourcing and services. Hite earned his Bachelor of Science degree in Finance from Indiana University. He has been actively involved with Junior Achievement for over 15 years and spent over five years as the local President of the Board of Directors for Junior Achievement.
Chief Executive Officer
As OrthoPediatrics’ Chief Executive Officer, Mark Throdahl is responsible for the strategic, operational, and financial performance of the Company. Mr. Throdahl is a former Group President of Zimmer, a worldwide leader in orthopedic implants, and brings a wealth of knowledge to the company through his successful experience as an operating executive, both domestic and internationally in the medical device, diagnostic, and pharmaceutical sectors. From 2001 to 2007 he served as Chief Executive of Consort Medical plc in London. During a 13‐year career at Becton Dickinson Co., he served as Senior Vice President of BD’s international organizations, President of the Drug Delivery Sector, and President of Nippon Becton Dickinson in Tokyo. He began his career at Mallinckrodt Group. Mr. Throdahl is a graduate of Princeton University and has a MBA from Harvard Business School.
David Pelizzon is a retired US Army officer who served almost 30 years on active duty in airborne and special operations units. Since his retirement from active duty in 2003, he has worked as a manufacturing executive in the US and Asia. Prior to starting Squadron Capital Mr. Pelizzon was the Managing Director of Precision Edge Holdings, Colson Associates in Chicago. Currently he is the President of Squadron Capital, a firm that primarily manages direct investments in operating companies and that also invests in private equity funds and special situations in support of the long term investment objectives of a Chicago based trust. Mr. Pelizzon is a graduate of the US Military Academy and has advanced degrees from Harvard University and the US Naval War College.
Chairman of the Board
Terry Schlotterback currently serves as the Chairman of the Board for OrthoPediatrics, bringing over 30 years of experience in the orthopedic industry. Prior to coming to OrthoPediatrics Terry worked for Zimmer Medical Holdings where he served in various executive leadership positions including President of Zimmer’s Trauma and Spinal Divisions. These divisions accounted for over $250 million in annual sales for the publicly traded orthopedic company. Prior to serving as Division President, he held senior executive positions in Sales, Marketing and Research and Development. Prior to Zimmer, Mr. Schlotterback served in senior management roles for Johnson & Johnson’s Depuy Orthopedics and Sports Medicine Division, Mitek Surgical Products, where he led Research, New Product Development and Business Development and the eventual acquisition of Mitek by Johnson & Johnson. Additionally, Mr. Schlotterback currently serves on the Advisory Board for the Indiana North Central Region of Elevate Ventures. He also contributes advisory services to the local Economic Development Corporation. He is President of the Warsaw Chapter of the StepStone Angels. He received his Bachelor of Science degree in Mechanical Engineering Technology from Purdue University.
Harald Ruf brings over 35 years of C-Suite level experience in a variety of industries including medical device OEM and medical device manufacturing. He currently serves as COO of Squadron Capital, LLC, the majority shareholder of OrthoPediatrics Corp. During his career, he has co-founded a number of successful companies in three different industries. He holds a Bachelor of Science degree in accounting from Brigham Young University and is a licensed CPA in Utah and California. Harald has also served as an officer and board member in local and national associations and has been recognized nationally for his distinguished service.
Kevin Unger is currently the CEO of Intrinsic Healthcare and has spent nearly two decades in the orthopedic industry. Prior to founding Intrinsic, Mr. Unger ran various medical device, medical technology, and orthopedic implant businesses. Most recently, he served as Global President of Orthofix, a spinal implant and biologics business with nearly $150M in global revenue. During his tenure at Orthofix, the business doubled its profit while growing revenues at an average of 3 times the market growth. Mr. Unger also ran a division of Stryker, where he was responsible for growing the business from $30M in revenue to over $150M in a 5-year period. He has additional experience in running global marketing departments and building sales organizations for larger multi-national orthopedic companies. Mr. Unger has significant experience in mergers and acquisitions, business turnaround and relocation, organizational restructuring and strategic planning. He is passionate about building collaborative cultures based on teamwork, accountability and service. All of this is supported by a servant leadership style that embraces transparency and recognizes the strengths in all team members.
Mr. Riccitelli currently serves as Chief Executive Officer of Pathnostics, a diagnostics company focused on improving antibiotic stewardship through better diagnosis and treatment selection for patients suffering from urinary tract infections. He has been a member of the Board of Directors for Precipio, Inc., [NASDAQ: PRPO] and has served as Chairman of the Board for PRPO since November 2017. Mr. Riccitelli also served on the board of directors of Exagen Diagnostics, Inc. from October 2011 to September 2014. Previously, Mr. Riccitelli served as President and CEO and a director on the board of directors of Signal Genetics, Inc., a publicly traded molecular diagnostic company focused on serving the needs of patients suffering from Multiple Myeloma. For 10 years, Mr. Riccitelli served as the Executive Vice President and Chief Operating Officer of Genoptix, Inc., a publicly traded diagnostic services company focused on the needs of community hematologists and oncologists. From 1995 to 2001, Mr. Riccitelli served in a number of R&D and general management leadership positions for Becton, Dickinson and Company, including most recently as a vice president and general manager and as a board member for BD Ventures, LLC., a venture capital fund. From 1989 to 1994, he served in a number of positions at Puritan-Bennett Corporation, including most recently as general manager. Mr. Riccitelli received a B.A. in Biology from Washington and Jefferson College and a M.S. Eng. degree from The University of Texas in Mechanical & Biomedical Engineering.